News
Cyprus Professor Finds Fusion of Delta And Omicron Variant
As per the Bloomberg News report on Saturday, January 8, Leondios Kostrikis, who is a professor in biological sciences at the University of Cyprus, the country has a new strain of COVID-19 which is a fusion of delta and...
News
Merck Doubles Its Pledge To Tackle Maternal Mortality Crisis
A startling figure indeed when we say that around the globe, a lady dies every 2 minutes, due to complications arising from childbirth and pregnancy. However, the fact remains that most of the situations are preventable, and to be...
News
CSafe Global Launches Real-Time Shipment Visibility for Passive Portfolios
CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today it has expanded its real-time shipment visibility platform and technology to the company’s VIP Parcel and Cell & Gene portfolios.
Customers who choose to include a...
IT & Data Management
Autism Clinical Trials Now Open On The TrialWire Platform
TrialWire(TM) is pleased to announce new Autism (ASD) clinical studies are now available on the TrialWire Platform. More than 6 million people have used TrialWire over the past few years to find clinical trials that are right for them...
News
IWK Packaging Systems Introduces Two Cost-Effective, Versatile Vertical Cartoners for Pharma & Personal Care Applications
IWK Packaging Systems, Inc., a manufacturer of premium cartoning and tube filling equipment for the pharmaceuticals and health & beauty sectors, has introduced a pair of versatile vertical cartoners – one intermittent, one continuous – that provide premium cartoning...
News
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, announced they have entered into a Development and Option agreement under which Pfizer will have the option to...
Drug Research
AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006
Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). NI006...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















